{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:13:49Z","timestamp":1793146429360,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T00:00:00Z","timestamp":1621814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary aldosteronism (PA) is a common cause of secondary hypertension and associated with higher incidence of new-onset atrial fibrillation (NOAF). However, the effects of surgical or medical therapies on preventing NOAF in PA patents remain unclear. The aim of this meta-analysis study was to assess the risk of NOAF among PA patients receiving mineralocorticoid receptor antagonist (MRA) treatment, PA patients receiving adrenalectomy, and patients with essential hypertension.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed the meta-analysis of the randomized or observational studies that investigated the incidence rate of NOAF in PA patients receiving MRA treatment versus PA patients receiving adrenalectomy from database inception until December 01, 2020 which were identified from PubMed, Embase, and Cochrane Library.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 172 related studies were reviewed, of which three fulfilled the inclusion criteria, including a total of 2,705 PA patients. The results of meta-analysis demonstrated a higher incidence of NOAF among the PA patients receiving MRA treatment compared to the PA patients receiving adrenalectomy (pooled odds ratio [OR]: 2.83, 95% confidence interval [CI]: 1.76\u20134.57 in the random effects model, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> = 0%). The pooled OR for the PA patients receiving MRA treatment compared to the patients with essential hypertension was 1.91 (95% CI: 1.11\u20133.28). The pooled OR for the PA patients receiving adrenalectomy compared to the patients with essential hypertension was 0.70 (95% CI: 0.28\u20131.79).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to the essential hypertension patients and the PA patients receiving adrenalectomy, the patients with PA receiving MRA treatment had a higher risk of NOAF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, identifier CRD42021222022.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.646933","type":"journal-article","created":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T06:43:52Z","timestamp":1621838632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies"],"prefix":"10.3389","volume":"12","author":[{"given":"Cheng-Hsuan","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ting","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Tin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Wei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Sheng","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5555\/uri:pii:0022214355900482","article-title":"Presidential Address: Part I. Painting Background Part Ii. Primary Aldosteronism, a New Clinical Syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1295438","article-title":"Prevalence of Primary Aldosteronism in Patient\u2019s Cohorts and in Population-Based Studies\u2013a Review of the Current Literature","volume":"44","author":"Hannemann","year":"2012","journal-title":"Horm Metab Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular Complications Associated With Primary Aldosteronism: A Controlled Cross-Sectional Study","volume":"62","author":"Savard","year":"2013","journal-title":"Hypertension"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2805","article-title":"Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism","volume":"98","author":"Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.tem.2008.01.006","article-title":"Primary Aldosteronism: Cardiovascular, Renal and Metabolic Implications","volume":"19","author":"Rossi","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2007.02775.x","article-title":"Primary Aldosteronism: Renaissance of a Syndrome","volume":"66","author":"Young","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-00426-y","article-title":"Left Ventricular Remodeling and Dysfunction in Primary Aldosteronism","volume":"35","author":"Tsai","year":"2021","journal-title":"J Hum Hypertens"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.08956","article-title":"Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble","volume":"69","author":"Seccia","year":"2017","journal-title":"Hypertension"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an Increased Rate of Cardiovascular Events in Patients With Primary Aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular Events and Target Organ Damage in Primary Aldosteronism Compared With Essential Hypertension: A Systematic Review and Meta-Analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/a-1141-5989","article-title":"Atrial Fibrillation in Primary Aldosteronism","volume":"52","author":"Pan","year":"2020","journal-title":"Horm Metab Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002273","article-title":"Atrial Fibrillation, Arterial Hypertension, and Primary Aldosteronism: A Dangerous and Unexpected Trio","volume":"38","author":"Manolis","year":"2020","journal-title":"J Hypertens"},{"key":"B14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jfma.2016.10.005","article-title":"2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the Management of Atrial Fibrillation","volume":"115","author":"Chiang","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5603\/KP.2016.0172","article-title":"2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jfma.2017.06.004","article-title":"Case Detection and Diagnosis of Primary Aldosteronism - The Consensus of Taiwan Society of Aldosteronism","volume":"116","author":"Wu","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism","volume":"50","author":"Catena","year":"2007","journal-title":"Hypertension"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1246185","article-title":"Mineralocorticoid Antagonists Treatment Versus Surgery in Primary Aldosteronism","volume":"42","author":"Catena","year":"2010","journal-title":"Horm Metab Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-122602","article-title":"Subtyping of Patients With Primary Aldosteronism: An Update","volume":"49","author":"Lenders","year":"2017","journal-title":"Horm Metab Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CRD.0000000000000281","article-title":"Primary Aldosteronism: Cardiovascular Risk, Diagnosis, and Management","volume":"28","author":"Pillai","year":"2020","journal-title":"Cardiol Rev"},{"key":"B21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jfma.2018.01.006","article-title":"Targeted Treatment of Primary Aldosteronism - The Consensus of Taiwan Society of Aldosteronism","volume":"118","author":"Huang","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e013699","DOI":"10.1161\/JAHA.119.013699","article-title":"Influence of Different Treatment Strategies on New-Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort-Based Study","volume":"9","author":"Pan","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B23","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Healthcare Interventions: Explanation and Elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"B24","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"Robins-I: A Tool for Assessing Risk of Bias in Non-Randomised Studies of Interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients At Long Term","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration With the European Association for Cardio-Thoracic Surgery (Eacts)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2116","article-title":"Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Conn\u2019s Registry","volume":"94","author":"Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002250","article-title":"Atrial Fibrillation as Presenting Sign of Primary Aldosteronism: Results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (Papphy) Study","volume":"38","author":"Seccia","year":"2020","journal-title":"J Hypertens"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.12.029","article-title":"Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"231","author":"Neefs","year":"2017","journal-title":"Int J Cardiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.519256","article-title":"The Mineralocorticoid Receptor Promotes Fibrotic Remodeling in Atrial Fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijcard.2013.06.046","article-title":"Cross-Talk Between Mineralocorticoid Receptor\/Angiotensin II Type 1 Receptor and Mitogen-Activated Protein Kinase Pathways Underlies Aldosterone-Induced Atrial Fibrotic Responses in HL-1 Cardiomyocytes","volume":"169","author":"Tsai","year":"2013","journal-title":"Int J Cardiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone Promotes Atrial Fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.06.1313","article-title":"Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications","volume":"66","author":"Dzeshka","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283550f93","article-title":"Adrenalectomy Reverses Myocardial Fibrosis in Patients With Primary Aldosteronism","volume":"30","author":"Lin","year":"2012","journal-title":"J Hypertens"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.06768","article-title":"Aldosterone Induces Tissue Inhibitor of Metalloproteinases-1 Expression and Further Contributes to Collagen Accumulation: From Clinical to Bench Studies","volume":"67","author":"Hung","year":"2016","journal-title":"Hypertension"},{"key":"B38","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cvr\/cvy013","article-title":"IL-6 Trans-Signalling Contributes to Aldosterone-Induced Cardiac Fibrosis","volume":"114","author":"Chou","year":"2018","journal-title":"Cardiovasc Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HJH.0000000000000619","article-title":"Circulating Tissue Inhibitor of Matrix Metalloproteinase-1 Is Associated With Aldosterone-Induced Diastolic Dysfunction","volume":"33","author":"Hung","year":"2015","journal-title":"J Hypertens"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2014.05.062","article-title":"Association Between Urine Aldosterone and Diastolic Function in Patients With Primary Aldosteronism and Essential Hypertension","volume":"47","author":"Chang","year":"2014","journal-title":"Clin Biochem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.113233","article-title":"Diastolic Dysfunction and Risk of Atrial Fibrillation: A Mechanistic Appraisal","volume":"126","author":"Rosenberg","year":"2012","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002070","article-title":"Clinical and Biochemical Outcomes After Adrenalectomy and Medical Treatment in Patients With Unilateral Primary Aldosteronism","volume":"37","author":"Katabami","year":"2019","journal-title":"J Hyperten"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Internal Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-Term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy With Treatment of Primary Aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001361","article-title":"Risk of New-Onset Diabetes Mellitus in Primary Aldosteronism: A Population Study Over 5 Years","volume":"35","author":"Wu","year":"2017","journal-title":"J Hyperten"},{"key":"B46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","article-title":"Quality of Life in Primary Aldosteronism: A Comparative Effectiveness Study of Adrenalectomy and Medical Treatment","volume":"103","author":"Velema","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3033","article-title":"Risk of Fracture in Primary Aldosteronism: A Population-Based Cohort Study","volume":"32","author":"Wu","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hyperten (Dallas Tex 1979)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.646933\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T06:43:55Z","timestamp":1621838635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.646933\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,24]]},"references-count":48,"alternative-id":["10.3389\/fendo.2021.646933"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.646933","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,24]]},"article-number":"646933"}}